Drug intelligence / Profile preview

yiqi huoxue jiedu decoction

Development stage: Unknown
Lead developer: Guang'anmen Hospital
Administration: Oral

Overview

Yiqi Huoxue Jiedu decoction is a Traditional Chinese Medicine (TCM) herbal formula developed by Guang'anmen Hospital of the Chinese Academy of Traditional Chinese Medicine. It is primarily investigated for the treatment of platinum-resistant epithelial ovarian cancer. The formula is designed to modulate the tumor microenvironment, specifically targeting macrophage polarization and interleukin-6 (IL-6) levels to overcome chemoresistance and improve clinical outcomes. In clinical trials, it is evaluated as an adjunct to standardized treatment to assess its impact on efficacy, quality of life, and TCM-related syndromes.

Other names: Yiqi Huoxue Jiedu formula

Targets

IL-6 (Interleukin 6)

Beyond the preview

Go deeper on yiqi huoxue jiedu decoction.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on yiqi huoxue jiedu decoction.

Explore the full profile